5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses

Study acronym: 5FU/C for AKs
StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Phase changed: not specified → Phase 1
  2. Re-verified, no change to tracked fields
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) has become standard of care among dermatologists for the field treatment of diffuse actinic keratoses (AKs). Data suggest that the addition of calcipotriene elicits a sustained T cell memory allowing for both short and long-term AK clearance. Our objective is to evaluate the efficacy, as well as, document the timing, severity and duration of local cutaneous reactions to topical treatment with 5FU/C for the treatment of AKs.
Trial Details
NCT Number NCT07794059
Lead Sponsor Cedars-Sinai Medical Center
Collaborators: The Cleveland Clinic
Conditions
(from sponsor)		 Actinic Keratoses
Related terms Keratosis, Actinic
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov